ArticleJournal of hepatocellular carcinoma2025
Hyper-Relapse Disease is a Special Pattern of Relapse of Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While hepatectomy is the major curative treatment of hepatocellular carcinoma (HCC), high relapsing rates were observed. Of note, quite a few cases of tumor relapses were characterized by very quick appearance and disseminated lesions. This study aims to identify a special pattern of tumor relapse and to evaluate the prognostic significance of it for HCC patients after curative hepatectomy. Methods: Medical records of HCC patients who underwent curative hepatectomy from January 1st 2018 to December 31st 2019 at Sun Yat-sen University Cancer Center (SYSUCC) were reviewed. Patients (n = 217) identified with tumor relapse during follow-up were included for analyses. Hyper-relapse disease (HRD) is defined as tumor relapse within 6 months from surgery, multiple intrahepatic lesions, as well as macrovascular invasion and/or extrahepatic metastasis. Kaplan-Meier method and Cox regression model were used to analyze overall survival (OS). Risk factors for HRD were explored using logistic regression analysis. External validation was performed using data from another center (n = 270). Results: In SYSUCC cohort, 66 (30%) encountered HRD, 118 (54%) had non-HRD early recurrence (ER), and 33 (16%) had late recurrence (LR). The HRD group had shorter OS than the non-HRD ER and the LR groups (P < 0.001). COX analysis identified HRD and PIVKA-II >1000 mAU/mL as risk factors of poorer OS. Intriguingly, local therapy (HR [95% CI]: 0.528 [0.290-0.961]) was associated with better OS in contrast to systemic therapies (HR [95% CI]: 1.120 [0.596-2.107]) after tumor relapse (p = 0.001). Logistic regression analysis identified microvascular invasion and HBV infection as independent factors associated with HRD. The worse outcome of the HRD group was validated in the external cohort, compared with the non-HRD ER group (P < 0.001). Conclusion: HRD is a special pattern of HCC relapse with poor prognosis after curative hepatectomy. Appropriate local therapy might improve patient survival after tumor relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.